US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) beat the expectations of Wall Street analysts with its sales and earnings figures for the second quarter of 2022.
The company’s quarterly revenues came in at a net total of $2.2 billion, a 22% increase on the same period of 2021 and 3% above the consensus estimate.
Adjusted diluted earnings per share were $3.60, which was in excess of the consensus and SVB Securities expectations and a 16% rise on a year ago.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze